Neutropenia and chronic neutropenic disorders
X4 Pharmaceuticals Inc. focuses on clinical research in congenital and acquired forms of primary autoimmune and idiopathic chronic neutropenia, with attention to patients affected by recurrent and serious infections.
- Absolute neutrophil count recovery
- Infection rate reduction
- Chronic neutropenic disorders
The sponsor’s work in this area is centered on restoring circulating neutrophil levels and addressing the clinical burden associated with persistent neutropenia.
WHIM syndrome
The company also funds research in Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome, a rare immunodeficiency disorder marked by low neutrophil counts and recurrent infections.
- Circulating neutrophils
- Hypogammaglobulinemia
- Recurrent infections
Clinical interest in this condition includes improvement of hematologic and immune-related features that contribute to disease severity.
Immunology and host defense
X4 Pharmaceuticals Inc. maintains a therapeutic focus on disorders of immune function where impaired innate defense and reduced neutrophil availability increase susceptibility to infection.
- Immune dysregulation
- Susceptibility to infection
- Myelokathexis
This research area reflects interest in conditions where immune cell trafficking and neutrophil mobilization are central to clinical management.
